Enzyme Replacement
Therapy (ERT)
Supplementing life-sustaining chemistry: A deep dive into the technology that replaces missing lysosomal enzymes.
01The Biology of Restoration
In LSD patients, the genetic blueprint for producing specific enzymes is broken. ERT provides a synthetic, recombinant version of these enzymes. These are not just plain proteins; they are biologically engineered with Mannose-6-Phosphate (M6P) address tags.
The Receptor Interaction
- Enzymes bind to high-affinity receptors (CI-M6PR) on the cell surface.
- The cell swallows the enzyme through a process called endocytosis.
- Inside the lysosome, the enzyme begins breaking down stored "cellular trash."
02Latest Technological Pointers
J-Brain Cargo® Technology
Proprietary system from JCR Pharmaceuticals that fuses enzymes with anti-transferrin receptor antibodies, allowing them to hitchhike across the Blood-Brain Barrier (BBB).
Denali TransportVehicle™
A high-affinity antibody platform that crosses the BBB and delivers enzymes like IDS for Hunter Syndrome (MPS II), now under FDA Priority Review.
PEGylation Enhancements
Chemical modification of enzymes to increase their half-life in the bloodstream, reducing the frequency of infusions and lowering immunogenicity.
Early Prenatal Intervention
Investigational trials showing that starting ERT in-utero can prevent irreversible organ damage before birth in diseases like Pompe and Hurler syndrome.
Combination with Chaperones
Using small-molecule pharmacological chaperones to stabilize recombinant enzymes, making them more effective at lower doses.
ERT Innovation Watch
Searching for the latest ERT breakthroughs...
Metabolic Directory
Finding the right COE (Centre of Excellence) is vital for starting ERT infusions.
Find COE Centers